## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.3% below STRENGTH zone (3.0-6.0%); PEG 159.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($19.17)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 31, 2025**
- Source: BioSpace | 20260101T130842 | Somewhat-Bullish | Relevance: 100%
- Sarepta Therapeutics granted equity awards on December 31, 2025, to 10 new hires as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These awards, totaling 55,118 restricted stock units (RSUs), will vest over four years, subject to continued employment. The initiative aims to attract and retain talent for the company's focus on precision genetic medicine for rare diseases.

**2. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)**
- Source: Business Wire | 20260101T070920 | Neutral | Relevance: 100%
- Sarepta Therapeutics, Inc. granted equity awards on December 31, 2025, to 10 newly hired individuals, as approved by its Compensation Committee under Sareptaâ€™s 2024 Employment Commencement Incentive Plan. These awards, totaling 55,118 restricted stock units (RSUs), were issued as a material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest yearly over four years, contingent on continued employment with Sarepta.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Wedbush | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Wedbush | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 4 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)
- Renaissance Technolo: 2.5% (+324.4%)

### Key Risks

1. Valuation stretched: PEG 159.2x requires aggressive growth execution.
2. High short interest (22.3%, 5.8 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 26.7% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.2B |
| Beta | 0.53 |
| 52W Range | $10.42 - $129.84 |
| Short Interest | 22.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 7.7 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 1.1% to -0.3% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.3pp (needs >3.0% for momentum thesis). Below SMA200 (0.73x), long-term trend not supportive. RSI neutral at 51. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.31% (CS: 31) | Neutral |
| RSI_14 | 50.7 | Neutral |
| MACD Histogram | -0.08 | Bearish |
| vs SMA20 | 0.980x | Below |
| vs SMA50 | 1.031x | Above |
| vs SMA200 | 0.733x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $21.31
- **Stop Loss:** $19.17 (10.0% risk)
- **Target:** $23.45 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 672
- **Position Value:** $14,320.32
- **Portfolio %:** 14.32%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*